ArticleMedicine2026
Memory B cells mediate the effect of gut microbiota glycolytic-glyoxylate pathway on lung cancer in never-smokers: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising incidence of lung cancer in never-smokers (LCINS) warrants investigation into novel etiological factors. Gut microbiota-associated metabolic pathways (e.g., glycolysis, glyoxylate degradation) and immune traits, such as the proportion of memory B cells, have been implicated in various diseases, but their causal roles in LCINS remain unclear. Using summary-level data from IEU OpenGWAS, we performed 2-sample Mendelian randomization (MR) to assess causal relationships of 412 gut microbiota features and 731 immune cell traits with LCINS. Mediation MR quantified immune cells' role in linking microbiota to LCINS. Twelve gut microbial taxa and 15 metabolic pathways (including glycolysis and glyoxylate degradation) demonstrated causal associations with LCINS (PIVW < .05). Separately, 36 peripheral immune cell traits showed causal links to LCINS. Mediation analysis further revealed that memory B cell ratio attenuated the effect of microbiota-derived metabolic pathways on LCINS by 7.53% (95% confidence interval: -2.63% to 17.70%; βmediation = -0.017, 95% confidence interval: -0.041 to 0.006). The ratio of memory B cells partially mediates the effect of gut microbiota-driven glycolysis/glyoxylate degradation on LCINS pathogenesis. These findings suggest the gut-immune-lung axis may inform preventive strategies for LCINS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.